Biomarkers in Obesity Research: Tools for Discovery by Pathway

Obesity is a disease with broad causes and effects. The study, diagnosis, and treatment of obesity have implications from the population level down to the individual (but interconnected) biological pathways in each person. The study of systems like adipokine signaling, appetite regulation, lipid metabolism, chronic inflammation, and insulin sensitivity help researchers gain better understanding of the pathways and disease mechanisms, leading to better diagnostic and therapeutic outcomes.

Vector Laboratories provides the trusted reagents, antibodies, and assay kits against targets relevant to these pathways for reproducible immunodetection results. With more than 50 years of immunodetection experience, our scientists provide the workflow support researchers trust to unravel the biological complexities of obesity.

Adipokines: Hormones from Fat Tissue

Adipose tissue does more than passively store energy—it is an active endocrine organ that secretes a range of cell-signaling proteins called adipokines that influence appetite, energy balance, and insulin sensitivity. Two of the most studied are leptin and adiponectin, the dysregulation of which are associated with obesity [1].

Leptin

Leptin is produced primarily by adipocytes and acts on hypothalamic receptors to suppress appetite and increase energy expenditure [1]. In lean individuals, circulating leptin levels track with fat mass. In obesity, leptin levels are typically elevated due to impairment of hypothalamic leptin signaling. This state of leptin resistance is a central feature of diet-induced obesity models and is actively studied in both rodent and human contexts. LSBio antibodies for leptin are validated for IHC and IF, and ELISA kits are available for streamlined detection and quantification in serum and plasma. Additionally, recombinant leptin protein is available for signaling and resistance studies.

Adiponectin

Adiponectin has the opposite relationship with obesity: levels decrease as fat mass increases, and low adiponectin is associated with insulin resistance and metabolic syndrome [1]. It improves insulin sensitivity through AMP kinase activation in liver and muscle and has anti-inflammatory effects in adipose tissue [2]. ELISA-based quantification of circulating adiponectin is a standard readout in metabolic disease studies; IHC-based detection is used to assess adiponectin expression in adipose tissue sections. LSBio carries antibodies and a range of ELISA kit formats for both human and rodent applications.

Appetite Regulation Hormones

Appetite is controlled by a network of peripheral signals that communicate with the hypothalamus to regulate food intake. Two key targets in obesity research, ghrelin and the leptin, sit at different ends of this axis.

Ghrelin

Ghrelin is the primary orexigenic hormone: it rises before meals, stimulates appetite, and falls after eating. Produced mainly by gastric X/A-like cells, it acts on growth hormone secretagogue receptor 1a (GHSR1a) in the hypothalamus to increase food intake and promote fat storage [3]. In obesity research, ghrelin dynamics are studied in the context of diet composition, bariatric surgery outcomes, and pharmacological appetite suppression. Antibodies for ghrelin support IHC localization in gastric tissue; ELISA kits measure active (acylated) or total ghrelin in plasma; recombinant ghrelin protein is used in receptor binding and functional assays.

Leptin and Leptin Receptor

Leptin is a hormone known to suppress appetite. The leptin receptor (LEP-R/OB-R) mediates leptin signaling in the hypothalamus and peripheral tissues. Mutations in LEP-R are one of the genetic causes of severe early-onset obesity [4]. In diet-induced obesity models, receptor expression and downstream JAK-STAT signaling are commonly assessed to distinguish true leptin deficiency from receptor-level resistance. Antibodies for LEP-R are used in IHC of hypothalamic and adipose tissue sections; soluble leptin receptor, which acts as a circulating leptin-binding protein, can be quantified by ELISA from serum or plasma samples.

Lipid Metabolism Markers

Excess energy storage in obesity is fundamentally a problem of lipid handling. Two proteins involved in fat uptake and trafficking are useful markers of adipose tissue function and metabolic status.

Lipoprotein Lipase (LPL)

LPL is expressed on the luminal surface of capillary endothelium and hydrolyzes triglycerides in circulating lipoproteins, releasing fatty acids for uptake by adjacent tissues. In adipose tissue, LPL activity promotes fat storage; in skeletal muscle, it supports fatty acid oxidation [5]. LPL activity and expression are altered in obesity and type 2 diabetes, and are frequently measured in studies of dietary fat metabolism, lipodystrophy, and pharmacological lipid lowering. LSBio offers an ELISA kit for LPL quantification and recombinant LPL protein for enzymatic and binding assays.

FABP4

Fatty acid binding protein 4 (FABP4, also called aP2) is highly expressed in adipocytes and macrophages and is involved in intracellular fatty acid transport. Circulating FABP4 is elevated in obesity and metabolic syndrome and correlates with insulin resistance, dyslipidemia, and cardiovascular risk [6]. It has attracted interest as both a biomarker and a potential drug target. LSBio antibodies for FABP4 are validated for IHC and IF in adipose tissue; an ELISA kit supports plasma quantification.

Inflammatory Biomarkers in Obesity

Obesity is associated with chronic, low-grade inflammation originating primarily from expanded and dysfunctional adipose tissue. Adipocytes and infiltrating macrophages in obese fat depots secrete pro-inflammatory cytokines that contribute to insulin resistance, endothelial dysfunction, and metabolic comorbidities. Three markers are particularly well-established in this context.

TNF-α

Tumor necrosis factor-alpha (TNF-α) was among the first cytokines identified as a mechanistic link between obesity and insulin resistance. Adipose-derived TNF-α promotes lipolysis [7], inhibits insulin receptor signaling through serine phosphorylation of IRS-1, and recruits immune cells to fat depots [8]. It remains a standard readout in adipose tissue inflammation studies and a reference target in metabolic inflammation models. LSBio carries multiple antibody formats for TNF-α, including recombinant formats from Absolute Antibody. ELISA kits support quantification from serum, plasma, or tissue lysates; recombinant protein is available for stimulation assays.

IL-6

Interleukin-6 is produced by both adipocytes and stromal vascular fraction cells in adipose tissue, and circulating IL-6 levels are elevated in obesity. Its role in metabolic disease is context-dependent: in acute settings it can improve insulin sensitivity through muscle-derived signaling, but chronically elevated IL-6 as seen in visceral obesity contributes to hepatic insulin resistance and acute phase protein production, including CRP [9]. Multiple antibody clones and ELISA formats for IL-6 are available through LSBio for human and rodent applications.

C-Reactive Protein

C-reactive protein (CRP) is produced by the liver in response to IL-6 and other pro-inflammatory signals and is widely used as a clinical marker of systemic inflammation. In obesity research, high-sensitivity CRP (hsCRP) is a standard readout that correlates with visceral fat mass, metabolic syndrome severity, and cardiovascular risk [10]. LSBio antibodies for CRP include both standard and high-sensitivity formats; ELISA kits are available for quantification from serum or plasma.

Insulin Resistance Markers

Insulin resistance is a defining feature of obesity-associated metabolic dysfunction. The core signaling pathway runs from insulin binding at the insulin receptor through IRS-1 phosphorylation, PI3K activation, and Akt-dependent GLUT4 translocation to the plasma membrane for glucose uptake. Each node in this pathway is a potential site of disruption and a target for measurement.

Insulin

Circulating insulin levels are elevated in obesity as the pancreas compensates for peripheral insulin resistance. Fasting hyperinsulinemia is an early marker of metabolic dysfunction before overt type 2 diabetes develops [11]. In research settings, insulin is measured by ELISA from plasma or serum; antibodies are used for IHC detection of pancreatic beta cells in tissue sections; recombinant insulin is used in in vitro signaling assays to stimulate the pathway in cell and organoid models.

GLUT4

Glucose transporter 4 is the insulin-responsive transporter responsible for glucose uptake in skeletal muscle and adipose tissue. In the basal state it is sequestered in intracellular vesicles; insulin signaling triggers its translocation to the plasma membrane. In obesity and type 2 diabetes, this translocation is impaired [12]. GLUT4 expression is commonly assessed by IHC in skeletal muscle and fat tissue biopsies; total GLUT4 protein can be quantified by ELISA from tissue lysates; recombinant GLUT4 protein supports binding and functional assays.

IRS-1

Insulin receptor substrate 1 is the primary intracellular docking protein for the activated insulin receptor. Its tyrosine phosphorylation initiates downstream PI3K-Akt signaling; its serine phosphorylation—promoted by TNF-α, free fatty acids, and inflammatory kinases—inhibits signaling and contributes to insulin resistance [13]. IRS-1 is measured by antibody-based methods in cell and tissue lysates; ELISA kits for total IRS-1 support quantitative analysis; recombinant protein is available for binding and pathway reconstitution assays.

Quick Reference Tables: Reagents for Obesity Biomarker Detection

The tables below list one featured product per target per reagent type. Full catalogs for each target are searchable at LSBio.com. Additional antibody formats including recombinant Fab fragments, species-switched formats, and functional-grade antibodies are available through Absolute Antibody by Vector Laboratories.

Adipokines

Appetite Regulation Hormones

Lipid Metabolism Markers

Inflammatory Biomarkers

Insulin Resistance Markers

Antibodies, ELISA kits, and recombinant proteins from LSBio, a Vector Laboratories company: LSBio.com

Absolute Antibody recombinant formats and reformatting services: AbsoluteAntibody.com

Explore Vector Laboratories' suite of immunodetection antibodies and reagents:

*Terms and conditions: Valid for U.S. direct customers only and for LSBio products only. Cannot be combined with any other promotions or discounts. Apply promo code LSBIO20 at checkout — please note that your cart total will not reflect the discounted price, but the 20% savings will be applied to your final credit card charge or institutional purchase order. To place an order, visit our website LSBio.com, email [email protected], or call (800) 227-6666 / (650) 697-3600. Promotion valid on orders placed no later than September 30, 2026, at 11:59 PM PT.

References

1. Clemente-Suárez, V. J., Redondo-Flórez, L., Beltrán-Velasco, A. I., Martín-Rodríguez, A., Martínez-Guardado, I., Navarro-Jiménez, E., Laborde-Cárdenas, C. C., & Tornero-Aguilera, J. F. (2023). The role of adipokines in health and disease. Biomedicines, 11(5), 1290. https://doi.org/10.3390/biomedicines11051290
2. Kubota, N., Yano, W., Kubota, T., Yamauchi, T., Itoh, S., Kumagai, H., Kozono, H., Takamoto, I., Okamoto, S., Shiuchi, T., Suzuki, R., Satoh, H., Tsuchida, A., Moroi, M., Sugi, K., Noda, T., Ebinuma, H., Ueta, Y., Kondo, T., Araki, E., … Kadowaki, T. (2007). Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metabolism, 6(1), 55–68. https://doi.org/10.1016/j.cmet.2007.06.003
3. Skoracka, K., Hryhorowicz, S., Schulz, P., Zawada, A., Ratajczak-Pawłowska, A. E., Rychter, A. M., Słomski, R., Dobrowolska, A., & Krela-Kaźmierczak, I. (2025). The role of leptin and ghrelin in the regulation of appetite in obesity. Peptides, 186, 171367. https://doi.org/10.1016/j.peptides.2025.171367
4. Gorska, E., Popko, K., Stelmaszczyk-Emmel, A., Ciepiela, O., Kucharska, A., & Wasik, M. (2010). Leptin receptors. European journal of medical research, 15 Suppl 2(Suppl 2), 50–54. https://doi.org/10.1186/2047-783x-15-s2-50
5. Pirahanchi, Y., Anoruo, M., & Sharma, S. (2023, July 30). Biochemistry, lipoprotein lipase. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK537040/
6. Furuhashi, M., Saitoh, S., Shimamoto, K., & Miura, T. (2015). Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases. Clinical Medicine Insights. Cardiology, 8(Suppl 3), 23–33. https://doi.org/10.4137/CMC.S17067  
7. Zhang, H. H., Halbleib, M., Ahmad, F., Manganiello, V. C., & Greenberg, A. S. (2002). Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes, 51(10), 2929–2935. https://doi.org/10.2337/diabetes.51.10.2929
8. Eswar, S., Rajagopalan, B., Ete, K., & Gattem, S. N. R. (2024). Serum tumor necrosis factor alpha (TNF-α) levels in obese and overweight adults: Correlations with metabolic syndrome and inflammatory markers. Cureus, 16(7), e64619. https://doi.org/10.7759/cureus.64619
9. Wueest, S., & Konrad, D. (2020). The controversial role of IL-6 in adipose tissue on obesity-induced dysregulation of glucose metabolism. American Journal of Physiology—Endocrinology and Metabolism, 319(3), E607–E613. https://doi.org/10.1152/ajpendo.00306.2020
10. Li, Q., Wang, Q., Xu, W., Ma, Y., Wang, Q., Eatman, D., You, S., Zou, J., Champion, J., Zhao, L., Cui, Y., Li, W., Deng, Y., Ma, L., Wu, B., Wang, G., Zhang, X., Wang, Q., Bayorh, M. A., & Song, Q. (2020). C-reactive protein causes adult-onset obesity through chronic inflammatory mechanism. Frontiers in Cell and Developmental Biology, 8, 18. https://doi.org/10.3389/fcell.2020.00018
11. Thomas, D. D., Corkey, B. E., Istfan, N. W., & Apovian, C. M. (2019). Hyperinsulinemia: An early indicator of metabolic dysfunction. Journal of the Endocrine Society, 3(9), 1727–1747. https://doi.org/10.1210/js.2019-00065
12. Gurley, J. M., Ilkayeva, O., Jackson, R. M., Griesel, B. A., White, P., Matsuzaki, S., Qaisar, R., Van Remmen, H., Humphries, K. M., Newgard, C. B., & Olson, A. L. (2016). Enhanced GLUT4-dependent glucose transport relieves nutrient stress in obese mice through changes in lipid and amino acid metabolism. Diabetes, 65(12), 3585–3597. https://doi.org/10.2337/db16-0709
13. Fernandez-Twinn, D. S., Alfaradhi, M. Z., Martin-Gronert, M. S., Duque-Guimaraes, D. E., Piekarz, A., Ferland-McCollough, D., Bushell, M., & Ozanne, S. E. (2014). Downregulation of IRS-1 in adipose tissue of offspring of obese mice is programmed cell-autonomously through post-transcriptional mechanisms. Molecular metabolism, 3(3), 325–333. https://doi.org/10.1016/j.molmet.2014.01.007